XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 6,923 $ 21,666
Accounts and other receivables   5,000
Prepaid and other current assets 697 1,540
Total current assets 7,620 28,206
Other assets, noncurrent 168 168
Right-of-use assets   66
Property and equipment, net   4
Total assets 12,394 28,444
Current liabilities:    
Accounts payable 5 194
Accrued compensation 720 2,582
Other accrued liabilities 2,068 1,452
Dividends payable   7,558
CVR derivative liability   5,000
Operating lease liability   38
Total current liabilities 2,793 16,824
CVR derivative liability, noncurrent 4,606  
Total liabilities 7,399 16,824
Commitments and Contingencies (Note 9)
Stockholders’ deficit:    
Common stock, $0.001 par value, 100,000,000 shares authorized; 37,974,892 and 37,756,574 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 37 37
Additional paid-in capital 384,797 389,210
Accumulated deficit (413,148) (410,936)
Total stockholders’ deficit (28,314) (21,689)
Total liabilities, redeemable convertible and redeemable preferred stock, and stockholders' deficit 12,394 28,444
Redeemable Convertible Preferred Stock    
Current liabilities:    
Redeemable preferred stock 33,309 33,309
Redeemable Preferred Stock    
Current liabilities:    
Redeemable preferred stock 0 $ 0
GC Biopharma Corp    
Current assets:    
Long-term receivable from GCBP $ 4,606